Doberstein Stephen K 4

What Happened Stephen K. Doberstein, a director of Forte Biosciences, was granted 18,353 restricted stock units (RSUs) on 2026-05-29. The award was granted at no cash cost to the reporting person (price $0.00) and is reported as a derivative award (Form 4 code A). This is a grant/award, not a purchase or sale—no shares were sold or transferred.

Key Details

• Transaction date: 2026-05-29; Form 4 filed 2026-06-02.
• Grant: 18,353 RSUs; acquisition price shown as $0.00 (derivative award).
• Vesting: Per footnote, 100% of the RSUs will vest on the date of the first annual meeting of stockholders that occurs after May 29, 2026, provided the reporting person continues as a Service Provider under the plan.
• RSU meaning: Each RSU is a contingent right to receive one share of Forte common stock upon vesting (per footnote).
• Shares owned following the transaction: not specified in the provided filing details.
• Filing timeliness: filing date and transaction date are shown; the filing does not state a late-file flag in the summary provided here.

Context RSU grants are common compensation for directors and employees and represent potential future issuance of shares if vesting conditions are met. Because this was an award (not a sale or market purchase), it does not by itself indicate buying or selling sentiment—it increases potential future dilution if/when RSUs vest and convert to shares.